Risdiplam (Evrysdi)


 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well patient clinician perspectives, a drug or class.
 The inform non-binding recommendations that help guide decisions Canada's federal, provincial, territorial governments, with exception Quebec.
 This review assesses risdiplam (Evrysdi), powder for oral solution.
 Indication:
 Pre-NOC: treatment spinal muscular atrophy;
 Final: atrophy in patients 2 months older.